Patent · US Active

Anti-Siglec-9 antibodies and methods of use thereof

US11667710B2 · kind B2 · utility

0Cited by

58References

16Claims

0Family size

Assignee

Alector LLC

Inventors

Arnon Rosenthal · Woodside, US
Kate Monroe · Berkeley, US
Seung-Joo Lee · Goyang-si, KR

Key dates

Filing date	Sep 10, 2020
Grant date	Jun 6, 2023
Priority date	—
Expiry date	Oct 15, 2040

Classification

Technology area (CPC G)Physics
CPC primaryG01N33/577
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.